S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma–final results of the randomized AIO MATEO phase II trial

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

(2022) Kohei Shitara et al.   NATURE

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

(2021) Jong-Mu Sun et al.   LANCET

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

(2021) Yelena Y Janjigian et al.   LANCET

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

(2020) Kohei Shitara et al.   JAMA Oncology

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

(2019) Salah-Eddin Al-Batran et al.   LANCET

Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial

(2019) Yasuhide Yamada et al.   Lancet Gastroenterology & Hepatology

A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer

(2017) Sook Ryun Park et al.   EUROPEAN JOURNAL OF CANCER

Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance)

(2015) Deirdre R. Pachman et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study

(2013) J.A. Ajani et al.   EUROPEAN JOURNAL OF CANCER

The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)

(2012) Salah-Eddin Al-Batran et al.   EUROPEAN JOURNAL OF CANCER

Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group)

(2012) Beate Schultheis et al.   INVESTIGATIONAL NEW DRUGS

Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer

(2011) Mitsuru Sasako et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility

(2011) S. B. Park et al.   ONCOLOGIST

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

(2009) Y.-K. Kang et al.   ANNALS OF ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

(2008) Salah-Eddin Al-Batran et al.   JOURNAL OF CLINICAL ONCOLOGY

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

(2008) Wasaburo Koizumi et al.   LANCET ONCOLOGY

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

(2008) David Cunningham et al.   NEW ENGLAND JOURNAL OF MEDICINE